Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin’s lymphoma

Nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL) accounts for approximately 5% of Hodgkin’s lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy aft...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2010-05, Vol.12 (5), p.384-386
Main Authors: Galán, Laura, Sánchez, Antonio C., Cantos, Blanca, Provencio, Mariano
Format: Article
Language:English
Subjects:
Aged
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents - therapeutic use
Case Reports
Chemotherapy, Adjuvant
Female
Hodgkin Disease - classification
Hodgkin Disease - drug therapy
Hodgkin Disease - immunology
Humans
Lymphocyte Activation - drug effects
Medicine
Medicine & Public Health
Oncology
Recurrence
Rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL) accounts for approximately 5% of Hodgkin’s lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-010-0521-9